Anne Letessier

Anne Letessier

Auto-generated profile, based on publicly available information

Anne Letessier

Université Paris Cité, INSERM, U1016, CNRS, UMR8104, Institut Cochin, F-75014 Paris, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDavid Rombaut
David Rombaut
CLCarine Lefèvre
Carine Lefèvre
TRTony Rached
Tony Rached
SBSabrina Bondu
Sabrina Bondu
ALAnne Letessier
Anne Letessier
MFMichaela Fontenay
Michaela Fontenay
Myelodysplastic syndromes (MDS) with mutated SF3B1 gene present features including a favourable outcome distinct from MDS with mutations in other splicing factor genes SRSF2 or U2AF1. Molecular bases of these divergences are poorly understood. Here we find that SF3B1-mutated MDS show reduced R-loop formation predominating in gene bodies associated with intron retention reduction, not found in U2AF1- or SRSF2-mutated MDS. Compared to erythroblasts from SRSF2- or U2AF1-mutated patients, SF3B1-mutated erythroblasts exhibit augmented DNA synthesis, accelerated replication forks, and single-stranded DNA exposure upon differentiation. Importantly, histone deacetylase inhibition using vorinostat restores R-loop formation, slows down DNA replication forks and improves SF3B1-mutated erythroblast differentiation. In conclusion, loss of R-loops with associated DNA replication stress represents a hallmark of SF3B1-mutated MDS ineffective erythropoiesis, which could be used as a therapeutic target.

14 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Benoit MiottoBenoit Miotto
Benoit Miotto
MGMorgane Le Gall
Morgane Le Gall
ALAnne Letessier
Anne Letessier
Genes encoding BAH-domain proteins play important roles in many physiological and pathological cellular processes via the recognition of methylated substrates. We systematically analyzed the transcription levels of these genes, as well as their association with clinical and molecular features, in 31 cancer types. Our analysis revealed the potential prognostic value of BAH-containing genes in many cancers, notably that high levels of ORC1 expression are significantly associated with both shorter overall and disease-free survival in adrenocortical carcinoma, brain lower grade glioma, liver hepatocellular carcinoma, and sarcoma. We further observed that these tumors with high levels of ORC1 share several commonalities independently of their tissue of origin. High levels of ORC1 expression are notably associated with pathways related to cell proliferation and pluripotency-related networks, as well as mutation burden, chromosomal alterations, and aneuploidy, to different extents. We further identified a set of common master and upstream molecular regulators in tumors with high ORC1 expression in these different tumor types as well as computationally predicted therapeutic compounds. We thus provide a resource focused on BAH-containing genes that may help distinguish tumors with poor outcomes while also highlighting mechanistic, prognostic, and therapeutic features across different cancer types.

15 November 2022 in Blood
Verified
Journal Article
Open access
DRDavid Rombaut
David Rombaut
CLCarine Lefevre
Carine Lefevre
BFBatoul Farhat
Batoul Farhat
SBSabrina Bondu
Sabrina Bondu
ALAnne Letessier
Anne Letessier
MFMichaela Fontenay
Michaela Fontenay
Introduction: Myelodysplastic syndromes (MDS) with SF3B1 mutation represent a subtype of hematopoietic stem cell disorders with bone marrow (BM) erythroid dyspl